Scarica l'app Stockscreener
4.62
6.48%
-0.32
Pre-mercato:
4.76
0.14
+3.03%
Passage Bio Inc Borsa (PASG) Ultime notizie
Passage Bio Inc (PASG) Cash Flow - TradingKey
PASG Stock Slumps 16% After-Hours — What’s Driving The Selloff? - Stocktwits
Passage Bio Inc (PASG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Passage Bio Inc (PASG) Institutional Confidence - TradingKey
Passage Bio Inc (PASG) Income Statement - TradingKey
Passage Bio Inc (PASG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Passage Bio Inc (PASG) Valuation: PE, PB & Fair Value Analysis - TradingKey
Passage Bio Inc (PASG) Balance Sheet - TradingKey
PASG|Passage Bio Inc|Price:4.570|Chg%:-0.370 - TradingKey
PASG|Passage Bio Inc|Price:4.940|Chg%:+0.040 - TradingKey
Passage Bio Inc (PASG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Passage Bio Inc (PASG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Passage Bio Inc (PASG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Passage Bio, Inc. Revenue Breakdown – NASDAQ:PASG - TradingView
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—CRNX, SLP, NCSM, and PASG - Morningstar
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--CRNX, SLP, NCSM, and PASG - Finansavisen
PASG Q2'26 Earnings: revenue estimate is 0 USD - TradingView
PASG Q1 2026 Earnings: Narrower-Than-Expected Loss Reflects Cost Discipline in Pre-Revenue PhaseHigh Growth Earnings - dars.gov.et
Passage Bio (PASG) to merge with Remix in $100M-backed oncology deal - Stock Titan
Form 4 Passage Bio Inc For: 22 July By Investing.com - Investing.com Nigeria
Passage Bio (NASDAQ: PASG) to merge with Remix Therapeutics in $346M stock deal - Stock Titan
Layoff Tracker: EMD Serono may trim R&D workforce by up to 70 - BioSpace
Passage Bio eyes gene therapy progress as Nasdaq-listed biotech develops CNS pipeline - Ad Hoc News
Passage Bio Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 7.3%Analyst Earnings Estimate - dars.gov.et
Passage Bio Inc. (PASG) Rises 7.3% as Momentum Lifts Shares Above Key SupportElliott Wave Count - DonanımHaber
Passage Bio (PASG) Surges 7.3% as Stock Tests Key Resistance at $5.25Sentiment Divergence - DonanımHaber
Passage Bio focuses on genetic medicine strategy as investors weigh long-term potential - ad-hoc-news.de
PASG Q1 2026 Earnings: Narrowed Losses Beat Estimates as Clinical Progress ContinuesNegative Surprise Momentum - dars.gov.et
SPRY, PASG, BOXL: Why these stocks plunged double digits in after-hours trading today - MSN
Lynx1 Capital Management LP Increases Stake in Passage Bio Inc - GuruFocus
Passage Bio, Inc. Financial Disclosures & SEC Filings - TradingView
Passage Bio explores gene therapy potential as investors weigh long-term prospects - AD HOC NEWS
Deal Watch: Boehringer Ingelheim Unveils Cancer Pacts With Immunai And Combotope - insights.citeline.com
Passage Bio (PASG) Stock Analysis Report | Financials & Insights - Benzinga
Lynx1 Capital Management Discloses Investment at Passage BIO with 21.0% Stake - TradingView
Passage BIO (NASDAQ: PASG) holder Lynx1 reports 21% ownership amid Remix deal - Stock Titan
Passage Bio (PASG) Slides 6% as Shares Test Key Support Near $4.35AD Line Divergence - dars.gov.et
PASGPassage Bio Inc Latest SEC Filings - Finviz
Latham & Watkins Advises Remix Therapeutics in Merger With Passage Bio - Legal Desire Media and Insights
Passage Bio (PASG) holder adds 50,055 shares in open-market buy - Stock Titan
Passage Bio to Merge With Remix in Deal Backed by $100 Million Financing - MyChesCo
PASG Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock Up 8.55%Profit Announcement - dars.gov.et
Weekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired - RTTNews
Passage Bio, Inc. Actuals & Estimates (NASDAQ:PASG) - TradingView
Enterprise value to EBIT forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Price to sales forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Price to book forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Price to earnings forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Enterprise value to EBITDA forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Enterprise value to revenue forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Passage Bio, Inc. Actuals & Estimates (BOATS:PASG) - TradingView
Baselake Partners (PASG) reports 235,058 shares, 7.3% ownership - Stock Titan
Remix Therapeutics secures $100M and a reverse merger - The Business Journals
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Remix to go public in reverse merger with once high-flying Passage Bio - BioPharma Dive
PASG Forecast — Price Target — Prediction for 2027 - TradingView
Which stocks are moving before the opening bell on Thursday? - ChartMill
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):